Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...

The clinical potential of mRNA was revealed with COVID-19 vaccines, but that was just the beginning. “Today, this Nobel prize–winning technology is being leveraged for many therapeutic applications, ...

A pandemic concentrates the mind wonderfully. Ever since the COVID-19 pandemic struck, government, academia, business, and the general public have demonstrated an intense interest in mRNA technologies ...

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...

Dublin, April 14, 2026 (GLOBE NEWSWIRE)-- The "Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Report 2026" has been added to ...

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...

A 3-year research program, funded by the FDA, aims to design the first continuous mRNA-manufacturing platform. Faculty at the Massachusetts Institute of Technology (MIT; MA, USA) will be leading a ...

(MENAFN- EIN Presswire) EINPresswire/ -- The global mRNA synthesis and manufacturing market is projected to experience steady growth, with the market value estimated to reach US$ 56.7 billion by 2026 ...

Despite a Moderna partnership that turned sour, AstraZeneca still wants a piece of the mRNA game. The British pharma company has signed a new mRNA manufacturing deal with China’s CanSino Biologics, ...

- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc.

STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA ...